Jonathan I. Epstein

Jonathan I. Epstein

Auto-generated profile, based on publicly available information

Jonathan I. Epstein

Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2005 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
JEJonathan I Epstein
Jonathan I Epstein
WAWilliam C Allsbrook
William C Allsbrook
MAMahul B Amin
Mahul B Amin
LELars L Egevad
Lars L Egevad

1 March 2016 in European Urology
Verified
Journal Article
Closed access
JEJonathan I. Epstein
Jonathan I. Epstein
MZMichael J. Zelefsky
Michael J. Zelefsky
DSDaniel D. Sjoberg
Daniel D. Sjoberg
JNJoel B. Nelson
Joel B. Nelson
LELars Egevad
Lars Egevad
EKEric A. Klein
Eric A. Klein

1 May 2012 in European Urology
Verified
Journal Article
Closed access
JEJonathan I. Epstein
Jonathan I. Epstein
ZFZhaoyong Feng
Zhaoyong Feng
BTBruce J. Trock
Bruce J. Trock
PPPhillip M. Pierorazio
Phillip M. Pierorazio

6 March 2013 in BJU International
Verified
Journal Article
Open access
PDF file
PPPhillip M. Pierorazio
Phillip M. Pierorazio
PWPatrick C. Walsh
Patrick C. Walsh
APAlan W. Partin
Alan W. Partin
JEJonathan I. Epstein
Jonathan I. Epstein
What's known on the subject? and What does the study add?: The G leason scoring system is a well‐established predictor of pathological stage and oncological outcomes for men with prostate cancer. Modifications throughout the last few decades – most recently by the I nternational S ociety of U rological P athology ( ISUP ) in 2005 – have attempted to improve the correlation between biopsy and radical prostatectomy G leason sum and better stratify patients to predict clinical outcomes. Based on these clinical outcomes and the excellent prognosis for patients with low G leason scores, we recommend G leason grades incorporating a prognostic grade grouping which accurately reflect prognosis and are clearly understood by physicians and patients alike. Objective: To investigate pathological and short‐term outcomes since the most recent G leason system modifications by the I nternational S ociety of U rological P athology ( ISUP ) in an attempt to divide the current G leason grading system into prognostically accurate G leason grade groups. Patients and Methods: We queried the J ohns H opkins R adical P rostatectomy D atabase (1982–2011), approved by the institutional review board, for men undergoing radical prostatectomy ( RP ) without a tertiary pattern since 2004 and identified 7869 men. Multivariable models were created using preoperative and postoperative variables; prognostic grade group ( G leason grade ≤6; 3 + 4; 4 + 3; 8; 9–10) was among the strongest predictors of biochemical recurrence‐free ( BFS ) survival. Results: Significant differences were noted among the G leason grade groups at biopsy; differences were noted in the race, PSA level, clinical stage, number of positive cores at biopsy and the maximum percentage of positive cores among the G leason grade groups at RP . With a median (range) follow‐up of 2 (1–7) years, 5‐year BFS rates for men with G leason grade ≤6, 3 + 4, 4 + 3, 8 and 9–10 tumours at biopsy were 94.6, 82.7, 65.1, 63.1 and 34.5%, respectively ( P < 0.001 for trend); and 96.6, 88.1, 69.7, 63.7 and 34.5%, respectively ( P < 0.001), based on RP pathology. Conclusions: The 2005 ISUP modifications to the G leason grading system for prostate carcinoma accurately categorize patients by pathological findings and short‐term biochemical outcomes but, while retaining the essence of the G leason system, there is a need for a change in its reporting to more closely reflect tumour behaviour. We propose reporting G leason grades, including prognostic grade groups which accurately reflect prognosis as follows: Gleason score ≤6 (prognostic grade group I); Gleason score 3+4=7 (prognostic grade group II); Gleason score 4+3=7 (prognostic grade group III); Gleason score 4+4=8 (prognostic grade group (IV); and Gleason score 9–10 (prognostic grade group (V).

1 February 2010 in Journal of Urology
Verified
Journal Article
Closed access
JEJonathan I. Epstein
Jonathan I. Epstein
An update is provided of the Gleason grading system, which has evolved significantly since its initial description. A search was performed using the MEDLINE(R) database and referenced lists of relevant studies to obtain articles concerning changes to the Gleason grading system. Since the introduction of the Gleason grading system more than 40 years ago many aspects of prostate cancer have changed, including prostate specific antigen testing, transrectal ultrasound guided prostate needle biopsy with greater sampling, immunohistochemistry for basal cells that changed the classification of prostate cancer and new prostate cancer variants. The system was updated at a 2005 consensus conference of international experts in urological pathology, under the auspices of the International Society of Urological Pathology. Gleason score 2-4 should rarely if ever be diagnosed on needle biopsy, certain patterns (ie poorly formed glands) originally considered Gleason pattern 3 are now considered Gleason pattern 4 and all cribriform cancer should be graded pattern 4. The grading of variants and subtypes of acinar adenocarcinoma of the prostate, including cancer with vacuoles, foamy gland carcinoma, ductal adenocarcinoma, pseudohyperplastic carcinoma and small cell carcinoma have also been modified. Other recent issues include reporting secondary patterns of lower and higher grades when present to a limited extent, and commenting on tertiary grade patterns which differ depending on whether the specimen is from needle biopsy or radical prostatectomy. Whereas there is little debate on the definition of tertiary pattern on needle biopsy, this issue is controversial in radical prostatectomy specimens. Although tertiary Gleason patterns are typically added to pathology reports, they are routinely omitted in practice since there is no simple way to incorporate them in predictive nomograms/tables, research studies and patient counseling. Thus, a modified radical prostatectomy Gleason scoring system was recently proposed to incorporate tertiary Gleason patterns in an intuitive fashion. For needle biopsy with different cores showing different grades, the current recommendation is to report the grades of each core separately, whereby the highest grade tumor is selected as the grade of the entire case to determine treatment, regardless of the percent involvement. After the 2005 consensus conference several studies confirmed the superiority of the modified Gleason system as well as its impact on urological practice. It is remarkable that nearly 40 years after its inception the Gleason grading system remains one of the most powerful prognostic factors for prostate cancer. This system has remained timely because of gradual adaptations by urological pathologists to accommodate the changing practice of medicine.

1 March 2006 in Journal of Urology
Verified
Journal Article
Closed access
JEJonathan I. Epstein
Jonathan I. Epstein
MHMehsati Herawi
Mehsati Herawi
We identified information critical for patient treatment on prostate needle biopsies diagnosed with prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma. A search was performed using the MEDLINE database and referenced lists of relevant studies to obtain articles addressing the significance of finding PIN or atypical foci suspicious for carcinoma on needle biopsy. There were certain results concerning PIN. 1) Low grade PIN should not be documented in pathology reports due to poor interobserver reproducibility and a relatively low risk of cancer following re-biopsy. 2) The expected incidence of HGPIN on needle biopsy is between 5% and 8%. 3) Although the diagnosis of HGPIN is subjective, interobserver reproducibility for its diagnosis is fairly high among urological pathologists, and yet only moderate among pathologists without special expertise in prostate pathology. 4) The median risk recorded in the literature for cancer following the diagnosis of HGPIN on needle biopsy is 24.1%, which is not much higher than the risk reported in the literature for repeat biopsy following a benign diagnosis. 5) The majority of publications that compared the risk of cancer in the same study following a needle biopsy diagnosis of HGPIN to the risk of cancer following a benign diagnosis on needle biopsy show no differences between the 2 groups. 6) Clinical and pathological parameters do not help stratify which men with HGPIN are at increased risk for a cancer diagnosis. 7) A major factor contributing to the decreased incidence of cancer following a diagnosis of HGPIN on needle biopsy in the contemporary era is related to increased needle biopsy core sampling, which detects many associated cancers on initial biopsy, such that re-biopsy, even with good sampling, does not detect many additional cancers. 8) It is recommended that men do not need routine repeat needle biopsy within the first year following the diagnosis of HGPIN, while further studies are needed to confirm whether routine repeat biopsies should be performed several years following a HGPIN diagnosis on needle biopsy. There were certain results concerning atypical glands suspicious for carcinoma. 1) An average of 5% of needle biopsy pathology reports are diagnosed as atypical glands suspicious for carcinoma. 2) Cases diagnosed as atypical have the highest likelihood of being changed upon expert review and urologists should consider sending such cases for consultation in an attempt to resolve the diagnosis as definitively benign or malignant before subjecting the patient to repeat biopsy. 3) Ancillary techniques using basal cell markers and AMACR (alpha-methyl-acyl-coenzyme A racemase) can decrease the number of atypical diagnoses, and yet one must use these techniques with caution since there are numerous false-positive and false-negative results. 4) The average risk of cancer following an atypical diagnosis is approximately 40%. 5) Clinical and pathological parameters do not help predict which men with an atypical diagnosis have cancer on repeat biopsy. 6) Repeat biopsy should include increased sampling of the initial atypical site, and adjacent ipsilateral and contralateral sites with routine sampling of all sextant sites. Therefore, it is critical for urologists to submit needle biopsy specimens in a manner in which the sextant location of each core can be determined. 7) All men with an atypical diagnosis need re-biopsy within 3 to 6 months. It is critical for urologists to distinguish between a diagnosis of HGPIN and that of atypical foci suspicious for cancer on needle biopsy. These 2 entities indicate different risks of carcinoma on re-biopsy and different recommendations for followup.